Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma

Hedberg, Matthew L.; Berry, Corbett T.; Moshiri, Ata S.; Xiang, Yan; Yeh, Christopher; Attilasoy, Cem; Capell, Brian C.; Seykora, John T.

doi:10.3390/ijms23073478

Cited by 42 publications

(42 citation statements)

References 254 publications

(355 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, poor oral bioavailability, acid sensitivity and some degrees of specificity constrict the clinical usage of cyclopamine [ 116 , 117 ]. Recently, several SMO inhibitors, including vismodegib (GDC-0449) and sonidegib (Erismodegib, NVP-LDE-225, LDE-225), have been engineered from cyclopamine and have gained success as targeted clinical cancer therapy [ 118 ] ( Table 1 ).…”

Section: Therapymentioning

confidence: 99%

Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma

Hoashi

Kanda

Saeki

2022

IJMS

View full text Add to dashboard Cite

Among human cutaneous malignancies, basal cell carcinoma is the most common. Solid advances in unveiling the molecular mechanisms of basal cell carcinoma have emerged in recent years. In Gorlin syndrome, which shows basal cell carcinoma predisposition, identification of the patched 1 gene (PTCH1) mutation was a dramatic breakthrough in understanding the carcinogenesis of basal cell carcinoma. PTCH1 plays a role in the hedgehog pathway, and dysregulations of this pathway are known to be crucial for the carcinogenesis of many types of cancers including sporadic as well as hereditary basal cell carcinoma. In this review, we summarize the clinical features, pathological features and hedgehog pathway as applied in basal cell carcinoma. Other crucial molecules, such as p53 and melanocortin-1 receptor are also discussed. Due to recent advances, therapeutic strategies based on the precise molecular mechanisms of basal cell carcinoma are emerging. Target therapies and biomarkers are also discussed.

show abstract

Section: Therapymentioning

confidence: 99%

Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma

Hoashi

Kanda

Saeki

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…cSCCs have a relatively low death rate compared to other cancers (e.g., <1–3% for cSCC c.f. 10% for colorectal cancer) and a relatively low rate of metastases (3–7%) [ 25 , 26 , 27 , 28 , 29 ]; however, the overall number of patients diagnosed every year mean that the number of deaths from cSCCs remains very high [ 14 , 25 , 30 ]. Notably, NMSCs including cSCC, has now overtaken melanoma worldwide for number of deaths [ 25 ].…”

Section: Need For Markers Of Malignant Sccmentioning

confidence: 99%

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

Chen

Yong

Zauner

et al. 2022

Cancers

View full text Add to dashboard Cite

Chondroitin sulfate (CS) proteoglycan 4 (CSPG4) is a cell surface proteoglycan that is currently under investigation as a marker of cancer malignancy, and as a potential target of anticancer drug treatment. CSPG4 acts as a driver of tumourigenesis by regulating turnover of the extracellular matrix (ECM) to promote tumour cell invasion, migration as well as inflammation and angiogenesis. While CSPG4 has been widely studied in certain malignancies, such as melanoma, evidence is emerging from global gene expression studies, which suggests a role for CSPG4 in squamous cell carcinoma (SCC). While relatively treatable, lack of widely agreed upon diagnostic markers for SCCs is problematic, especially for clinicians managing certain patients, including those who are aged or infirm, as well as those with underlying conditions such as epidermolysis bullosa (EB), for which a delayed diagnosis is likely lethal. In this review, we have discussed the structure of CSPG4, and quantitatively analysed CSPG4 expression in the tissues and pathologies where it has been identified to determine the usefulness of CSPG4 expression as a diagnostic marker and therapeutic target in management of malignant SCC.

show abstract

“…cSCCs have a relatively low death rate compared to other cancers (e.g., < 1 -3 % for cSCC c.f. 10 % for colorectal cancer) and a relatively low rate of metastases (3 -7 %) [25][26][27][28][29]; however, the overall number of patients diagnosed every year mean that the number of deaths from cSCCs remains very high [14,24,30]. Notably, NMSCs including cSCC, has now overtaken melanoma worldwide for number of deaths [25].…”

Section: Need For Markers Of Malignant Sccmentioning

confidence: 99%

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

Chen¹,

Yong²,

Zauner³

et al. 2022

Preprint

View full text Add to dashboard Cite

Chondroitin sulfate (CS) proteoglycan 4 (CSPG4) is a cell surface proteoglycan that is currently under investigation as a marker of cancer malignancy, and as a potential target of anticancer drug treatment. CSPG4 acts as a driver of tumourigenesis by regulating turnover of the extracellular matrix (ECM) to promote tumour cell invasion, migration as well as inflammation and angiogenesis. While CSPG4 has been widely studied in certain malignancies, such as melanoma, evidence is emerging from global gene expression studies, which suggests a role for CSPG4 in squamous cell carcinoma (SCC). While relatively treatable, lack of widely agreed upon diagnostic markers for SCCs is problematic, especially for clinicians managing certain patients, including those who are aged or infirm, as well as those with underlying conditions such as epidermolysis bullosa (EB), for which a delayed diagnosis is likely lethal. In this review, we have discussed the structure of CSPG4, and quantitatively analysed CSPG4 expression in the tissues and pathologies where it has been identified. The aim of this review has been to collate the information available from functional studies and recent transcriptome analysis to determine the usefulness of CSPG4 expression as a diagnostic marker and therapeutic target in management of malignant SCC.

show abstract

Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma

Cited by 42 publications

References 254 publications

Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma

Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

Contact Info

Product

Resources

About